0001654954-19-014167.txt : 20191223 0001654954-19-014167.hdr.sgml : 20191223 20191223073939 ACCESSION NUMBER: 0001654954-19-014167 CONFORMED SUBMISSION TYPE: 424B5 PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20191223 DATE AS OF CHANGE: 20191223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B5 SEC ACT: 1933 Act SEC FILE NUMBER: 333-233636 FILM NUMBER: 191303441 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 424B5 1 v122319_424b5.htm 424B5 Blueprint
 
 
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-233636
 
Calculation of Registration Fee
 
 
 
 
 
 
 
 
 
 
 
Amount
to be Registered

Proposed Maximum Offering Price Per Share
 
Proposed Maximum Aggregate
Offering Price
 
Amount of
Registration Fee (1)
Common Stock, par value $0.001 per share
 
5,434,783
 
$9.20
 
$50,000,000
 
$6,490

(1) Calculated in accordance with Rule 457 under the Securities Act of 1933, as amended.
 

PROSPECTUS SUPPLEMENT
(To the Prospectus dated September 5, 2019)
 
 

 
5,434,783 Shares
Common Stock
  
 
 
We are offering 5,434,783 shares of our common stock, par value $0.001 per share, directly to an institutional investor pursuant to a securities purchase agreement dated December 22, 2019 (the “Securities Purchase Agreement”), this prospectus supplement, and the accompanying prospectus. The common stock will be purchased at a negotiated price of $9.20 per share. The offering will result in total proceeds (before expenses) to the Company of $50.0 million. There are no underwriting or placement agent fees associated with the offering.
 
Our common stock is listed on the Nasdaq Capital Market under the symbol “TGTX.” On December 20, 2019, the closing sale price of our common stock was $10.11 per share.
 
Investing in these securities involves a high degree of risk. Before buyin  g shares of our common stock, you should carefully consider the risk factors described in “Risk Factors” in our annual report on Form 10-K and our other reports filed with the Securities and Exchange Commission which are incorporated into this prospect supplement and accompanying prospectus by reference.
 
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined whether this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
 
December 23, 2019.
 
 

GRAPHIC 2 tglogo.jpg IMAGE begin 644 tglogo.jpg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